Evidence map›Paper›PMID 29224373›Full record

ReviewExpert opinion on pharmacotherapy2018

Pharmacotherapy and treatment options for HIV-associated nephropathy.

Steven Menez, Mohamad Hanouneh, Blaithin A McMahon, Derek M Fine, Mohamed G Atta

Abstract readReview
In one paragraph

Review in Expert opinion on pharmacotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Updates on HIV and Kidney Disease.Current HIV/AIDS reports · 2023
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Steven Meneza Johns Hopkins Department of Medicine , Division of Nephrology , Baltimore , MD , US.
Mohamad Hanouneha Johns Hopkins Department of Medicine , Division of Nephrology , Baltimore , MD , US.
Blaithin A McMahona Johns Hopkins Department of Medicine , Division of Nephrology , Baltimore , MD , US.ORCID 0000-0001-8585-2787
Derek M Finea Johns Hopkins Department of Medicine , Division of Nephrology , Baltimore , MD , US.
Mohamed G Attaa Johns Hopkins Department of Medicine , Division of Nephrology , Baltimore , MD , US.

Funding

VIRAL PATHOGENESIS OF HIV ASSOCIATED NEPHROPATHYP01DK056492 · NIDDK · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI HE, JOHN CIJIANG · 1999 to 2021
$27.8M
CARDIOVASCULAR EPIDEMIOLOGY INSTITUTIONAL TRAININGT32HL007024 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Elizabeth Selvin · 1985 to 2026
$17.5M
NHLBI NIH HHS T32 HL007024NIDDK NIH HHS P01 DK056492
6 · The paper itself

Abstract

introductionHuman immunodeficiency virus (HIV) remains a worldwide disease with significant mortality and morbidity. There are a multitude of HIV-related kidney diseases including HIV-associated nephropathy (HIVAN) most prominently. The risk of developing HIVAN increases with decreasing CD4 count, higher viral load, and based on genetic factors. The mortality rate for those with HIVAN-end stage renal disease (ESRD) remains 2.5-3 times higher than ESRD patients without HIVAN. AREAS COVERED: The epidemiology of HIVAN, particularly risk assessment, will be explored in this review. Further, the pathogenesis of HIVAN, from viral-specific renal expression to the role of genetics as well as characteristic renal pathology will be described. Diagnosis and management of HIVAN will be addressed, with an emphasis on various treatment strategies including medication, dialysis, and kidney transplantation. EXPERT OPINION: HIVAN is associated with a high risk for progression to ESRD and increased mortality. The backbone of HIVAN therapy remains combined anti-retroviral therapy (cART), while adjunctive therapies including RAAS blockade and prednisone, should be considered. In those who progress to ESRD, dialysis remains the mainstay of management, though increasing evidence has demonstrated that kidney transplantation can be effective in those with controlled HIV disease.

Indexed as

AIDS-Associated NephropathyCD4 Lymphocyte CountDisease ProgressionHIV InfectionsHumansKidneyKidney Failure, ChronicKidney TransplantationRenal DialysisViral LoaddialysisESRDHIVHIVANkidney biopsytransplantation

Identifiers

PMID29224373
PMCPMC6381591
OpenAlexW2771086421

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.